Y-H Im

Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients

Y H Park, M J Park, S H Ji et al. · British Journal of Cancer · 2009 · 175 citations · Full text

Medicine, Oncology, Breast Oncology +16

Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial

Yeon Hee Park, Tae‐Yong Kim, Gun Min Kim et al. · The Lancet Oncology · 2019 · 130 citations

Medicine, Oncology, Pharmacology +16

Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer

DJ Slamon, SM Swain, Marc Buyse et al. · Cancer Research · 2013 · 92 citations

Medicine, Oncology, Pharmacology +17

Clinical significance of CD151 overexpression in subtypes of invasive breast cancer

Mi Kwon, S Park, Jung Yun Choi et al. · British Journal of Cancer · 2012 · 88 citations · Full text

Medicine, Oncology, Pathology +13

VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up

Sibylle Loibl, Jacek Jassem, Amir Sonnenblick et al. · Annals of Oncology · 2022 · 52 citations · Full text

Medicine, Immunology, Oncology +14